MEDICAL SERVICES

Specialties

Departments

Programs

Languages

  • English

  • Cantonese

  • Mandarin Chinese

EDUCATION

Medical School

  • University of Florida College of Medicine , 2010 , Gainesville , FL

Internship

  • Boston Children's Hospital , 2011 , Boston , MA

Residency

  • Boston Children's Hospital , 2013 , Boston , MA

Fellowship

  • Boston Children's Hospital , 2016 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Rheumatology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. 2021 05; 147(5). View abstract
  2. Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India. Arthritis Rheumatol. 2021 02; 73(2):276-285. View abstract
  3. Reply. Arthritis Rheumatol. 2021 01; 73(1):176-178. View abstract
  4. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View abstract
  5. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 11; 146(5):925-937. View abstract
  6. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. Pediatrics. 2020 11; 146(5). View abstract
  7. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020 11; 146(5):1194-1200.e1. View abstract
  8. NF-E2-Related Factor 2 Regulates Interferon Receptor Expression and Alters Macrophage Polarization in Lupus. Arthritis Rheumatol. 2020 10; 72(10):1707-1720. View abstract
  9. Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome. Front Immunol. 2020; 11:985. View abstract
  10. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020 07; 72(7):1059-1063. View abstract
  11. Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. Clin Immunol. 2020 06; 215:108411. View abstract
  12. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020 04 01; 130(4):1669-1682. View abstract
  13. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View abstract
  14. Analysis of peripheral blood ADA1 and ADA2 levels in children and adults. Response to: 'Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum' by Gao et al. Ann Rheum Dis. 2020 Feb 13. View abstract
  15. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020 06; 145(6):1664-1672.e10. View abstract
  16. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature. 2020 01; 577(7788):109-114. View abstract
  17. Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon. Arthritis Rheumatol. 2020 01; 72(1):100-113. View abstract
  18. Giant Cell Tumor of Tendon Sheath and Tendinopathy as Early Features of Early Onset Sarcoidosis. Front Pediatr. 2019; 7:480. View abstract
  19. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View abstract
  20. High-dimensional analysis reveals a pathogenic role of inflammatory monocytes in experimental diffuse alveolar hemorrhage. JCI Insight. 2019 08 08; 4(15). View abstract
  21. NETing the mechanism of inflammation in DADA2. Blood. 2019 07 25; 134(4):338-339. View abstract
  22. Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets. Elife. 2019 05 01; 8. View abstract
  23. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics. 2019 05; 143(5). View abstract
  24. Differential attenuation of ß2 integrin-dependent and -independent neutrophil migration by Ly6G ligation. Blood Adv. 2019 02 12; 3(3):256-267. View abstract
  25. Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2. Front Pediatr. 2018; 6:282. View abstract
  26. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol. 2018 10; 142(4):1363-1365.e8. View abstract
  27. Stromal cell cadherin-11 regulates adipose tissue inflammation and diabetes. J Clin Invest. 2017 Sep 01; 127(9):3300-3312. View abstract
  28. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Sci Immunol. 2017 May 26; 2(11). View abstract
  29. Pathogenesis of Diffuse Alveolar Hemorrhage in Murine Lupus. Arthritis Rheumatol. 2017 06; 69(6):1280-1293. View abstract
  30. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. Laryngoscope. 2017 01; 127(1):233-240. View abstract
  31. Renal involvement in the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) disorder. Pediatr Nephrol. 2015 Jul; 30(7):1197-202. View abstract
  32. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome associated with neonatal epidermolysis bullosa acquisita. Pediatr Dermatol. 2015 May-Jun; 32(3):e74-7. View abstract
  33. Hypercalcemia and miliary sarcoidosis in a 15-year-old boy. Arthritis Rheum. 2013 Aug; 65(8):2112. View abstract
  34. Ly6 family proteins in neutrophil biology. J Leukoc Biol. 2013 Oct; 94(4):585-94. View abstract
  35. Maintenance of anti-Sm/RNP autoantibody production by plasma cells residing in ectopic lymphoid tissue and bone marrow memory B cells. J Immunol. 2013 Apr 15; 190(8):3916-27. View abstract
  36. Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus. J Immunol. 2012 Apr 15; 188(8):4113-21. View abstract
  37. Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane. Lab Invest. 2011 Oct; 91(10):1540-50. View abstract
  38. B cells enhance early innate immune responses during bacterial sepsis. J Exp Med. 2011 Aug 01; 208(8):1673-82. View abstract
  39. IL-1a modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. J Immunol. 2011 Feb 01; 186(3):1747-54. View abstract
  40. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 2010 Oct; 58(5):355-64. View abstract
  41. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(3):R90. View abstract
  42. Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus. J Neuroimmunol. 2010 Jun; 223(1-2):13-9. View abstract
  43. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol. 2009 Nov; 175(5):2023-33. View abstract
  44. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009 Sep; 30(9):455-64. View abstract
  45. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis. 2009 Nov; 54(5):945-53. View abstract
  46. B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. J Immunol. 2009 Apr 01; 182(7):4226-36. View abstract
  47. Increased expression of FcgammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res Ther. 2009; 11(1):R6. View abstract
  48. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med. 2008 Dec 22; 205(13):2995-3006. View abstract
  49. Colocalization of antigen-specific B and T cells within ectopic lymphoid tissue following immunization with exogenous antigen. J Immunol. 2008 Sep 01; 181(5):3259-67. View abstract
  50. A novel type I IFN-producing cell subset in murine lupus. J Immunol. 2008 Apr 01; 180(7):5101-8. View abstract
  51. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007 Nov; 56(11):3770-83. View abstract
  52. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007 Nov; 56(11):3759-69. View abstract
  53. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol. 2006 Apr; 168(4):1227-40. View abstract
  54. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine. 2006 May 08; 24(19):4035-40. View abstract
  55. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol. 2005 Dec; 117(3):238-50. View abstract
  56. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol. 2005 Mar 15; 174(6):3650-7. View abstract